Hexavalent vaccines: What can we learn from head-to-head studies?-Reference-Cited by-同舟云学术

Hexavalent vaccines: What can we learn from head-to-head studies?

Published:2021-10 Issue:41 Volume:39 Page:6025-6036
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Knuf Markus,Haas Hervé,Garcia-Corbeira Pilar,Turriani Elisa^ORCID,Mukherjee Piyali^ORCID,Janssens Winnie^ORCID,Berlaimont Valérie

Funder

GlaxoSmithKline

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference54 articles.

1. Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer;Dolhain;Expert Rev Vacc,2018

2. European Medicines Agency (EMA). Hexavac [diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis b (recombinant) and haemophilus influenzae type b conjugate vaccine, adjuvanted]. Withdrawal of marketing authorisation in the European Union, https://www.ema.europa.eu/en/documents/public-statement/public-statement-hexavac-withdrawal-marketing-authorisation-european-union_en.pdf ; 2012 [accessed 05 October 2020].

3. European Medicines Agency (EMA). Infanrix Hexa EMA summary of product characteristics, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000296/WC500032505.pdf ; 2020 [accessed 05 August 2020].

4. European Medicines Agency (EMA). Hexyon EMA summary of product characteristics, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/002796/WC500145758.pdf ; 2020 [accessed 05 August 2020].

5. European Medicines Agency (EMA). Vaxelis EMA summary of product characteristics, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003982/WC500202435.pdf ; 2020 [accessed 05 August 2020].

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A worldwide overview for hexavalent vaccines and a glimpse into Turkiye’s perspective;Human Vaccines & Immunotherapeutics;2024-05-23

2. Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries;Human Vaccines & Immunotherapeutics;2023-01-02

3. A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients;Expert Review of Vaccines;2022-12-26

4. Real life hexavalent vaccination among children as a practical guide for public health professionals: Four years (from 2016 to 2019) of clinical practice in Sicily, Italy;Human Vaccines & Immunotherapeutics;2022-11-03

5. Demonstration of durable hepatitis B immune memory in children vaccinated with a DTaP5-IPV-HepB-Hib infant-toddler series 7 to 8 years previously;Human Vaccines & Immunotherapeutics;2022-06-02